These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
793 related items for PubMed ID: 15836565
1. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group. Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565 [Abstract] [Full Text] [Related]
2. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group. Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567 [Abstract] [Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [Abstract] [Full Text] [Related]
4. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group. Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492 [Abstract] [Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
6. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group. Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038 [Abstract] [Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC. Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [Abstract] [Full Text] [Related]
8. Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study. Zirovich MD, Pangarkar SS, Manh C, Chen L, Vangala S, Elashoff DA, Izuchukwu IS. Mil Med; 2021 May 03; 186(5-6):493-499. PubMed ID: 33241323 [Abstract] [Full Text] [Related]
9. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Mathew NT, Kailasam J, Meadors L. Headache; 2008 Feb 03; 48(2):194-200. PubMed ID: 17868356 [Abstract] [Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. Cephalalgia; 2010 Jul 03; 30(7):793-803. PubMed ID: 20647170 [Abstract] [Full Text] [Related]
11. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Blumenfeld A. Headache; 2003 Sep 03; 43(8):853-60. PubMed ID: 12940806 [Abstract] [Full Text] [Related]
12. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. Cephalalgia; 2010 Jul 03; 30(7):804-14. PubMed ID: 20647171 [Abstract] [Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235 [Abstract] [Full Text] [Related]
14. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Ondo WG, Vuong KD, Derman HS. Cephalalgia; 2004 Jan 15; 24(1):60-5. PubMed ID: 14687015 [Abstract] [Full Text] [Related]
15. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, Topiramate Chronic Migraine Study Group. Headache; 2007 Feb 15; 47(2):170-80. PubMed ID: 17300356 [Abstract] [Full Text] [Related]
16. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G. J Headache Pain; 2011 Aug 15; 12(4):427-33. PubMed ID: 21499747 [Abstract] [Full Text] [Related]
18. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. Farinelli I, Coloprisco G, De Filippis S, Martelletti P. J Headache Pain; 2006 Dec 15; 7(6):407-12. PubMed ID: 17149565 [Abstract] [Full Text] [Related]
19. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C. Cephalalgia; 2006 Jul 15; 26(7):790-800. PubMed ID: 16776693 [Abstract] [Full Text] [Related]
20. Is botulinum toxin A effective for the treatment of plantar fasciitis? Peterlein CD, Funk JF, Hölscher A, Schuh A, Placzek R. Clin J Pain; 2012 Jul 15; 28(6):527-33. PubMed ID: 22673486 [Abstract] [Full Text] [Related] Page: [Next] [New Search]